This is the way
It really isn’t enough to say once again we were spot on, and analysts were dead wrong. Momma Kliff didn’t like it when any of her children gloated preferring instead that our accomplishments stand on their own merit. Mom always said when you do a good job people will notice, when others screw up, they’ll notice that more and appreciate you more. Well, there is no question the analysts screwed...
The Floodgates are set to open.
Today we learned that Dexcom was among the investors in a Series B funding round for diabetes/obesity startup Signos. The Friday before Ilant Health a “new virtual provider targeting obesity treatment” launched with $3 million in funding. I’m pretty sure there are more that we missed but this is just the beginning. Get ready for investor money to start pouring into what we are calling the Ozempic Cost Containment (OCC)...
Exhibit One
Mark Twain once stated that reports of his demise have been greatly exaggerated. The same can be said for how sales of Ozempic and all the other GLP-1’s would impact sales of diabetes tech. We got our first set of facts toady when Abbott reported strong growth for sales of Libre. This really should not come as a surprise as once again we were right, and the analysts were wrong. We’ll...
Off the reservation
This is getting just a little no this getting way out of hand. Last week Novo Nordisk raised sales and profits estimates. The Washington Post publishes an article on how Ozempic is changing everything from food sales to the size of airline seats. Fans of Lady Gaga are calling her Ozempic Gaga given her recent weight loss. Industries and companies which aren’t remotely impacted by Ozempic are being impacted. The...
Swimming upstream
Years ago, Diabetic Investor felt alone in the wilderness when we were the only publication that came out against Exubera. Everyone and we do mean everyone thought this was going to be a multi-billion-dollar drug. That was everyone but us. We accurately predicted that Exubera would be a colossal failure heck we even said so on CNBC. We swam upstream again when all the analysts said no one would use Byetta...
Diabetes Tech Signs of life
Mark Twain once said, “Reports of my death have been greatly exaggerated”. Given the way shares of Dexcom, Insulet and Tandem have been performing one would be under the impression they have been given up for dead. That the analysts for once are right and that Ozempic, Wegovy and Mounjaro have put the nail in the diabetes tech coffin. Well maybe not, maybe we’ve been right all along and while there...
Insulet scores a big win!
Before we begin today our thoughts and prayers are with the people of Israel. Like so many we stand with Israel and pray for a quick end to the war. In a different type of war Insulet has scored a major victory in the IP lawsuit against EOFlow and by default Medtronic. On Friday a Federal judge granted Insulet’s request for a restraining order – the ruling states: 1. EOFlow is hereby...